1. Home
  2. GNSS vs KZIA Comparison

GNSS vs KZIA Comparison

Compare GNSS & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GNSS

Genasys Inc.

HOLD

Current Price

$1.68

Market Cap

85.6M

ML Signal

HOLD

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

HOLD

Current Price

$14.58

Market Cap

100.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNSS
KZIA
Founded
1992
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
85.6M
100.8M
IPO Year
1996
2002

Fundamental Metrics

Financial Performance
Metric
GNSS
KZIA
Price
$1.68
$14.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$4.75
$19.50
AVG Volume (30 Days)
127.2K
182.2K
Earning Date
05-11-2026
06-04-2026
Dividend Yield
N/A
N/A
EPS Growth
44.44
N/A
EPS
N/A
N/A
Revenue
$26,306,790.00
N/A
Revenue This Year
$80.08
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
29.50
N/A
52 Week Low
$1.40
$4.86
52 Week High
$2.70
$17.40

Technical Indicators

Market Signals
Indicator
GNSS
KZIA
Relative Strength Index (RSI) 39.33 59.82
Support Level $1.40 $5.62
Resistance Level $2.06 $14.57
Average True Range (ATR) 0.09 1.08
MACD -0.02 0.14
Stochastic Oscillator 26.05 81.64

Price Performance

Historical Comparison
GNSS
KZIA

About GNSS Genasys Inc.

Genasys Inc is a provider of Protective Communication solutions, including Genasys Protect software platform and Long Range Acoustic Device (LRAD). Its software platform receives information from variety of sensors and Internet-of-Things (IoT) inputs to collect real-time information on developing and active emergency situations. Genasys uses this information to create and disseminate alerts, warnings, notifications, and instructions through multiple channels before, during, and after public safety and enterprise threats, critical events, and other crisis situations. The Company operates in two business segments: Hardware and Software and its markets are North and South America, Europe, Middle East and Asia. Key revenue is generated from Hardware.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: